X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of rare diseases and immune system disorders. The company's lead product candidate, mavorixafor, is in late-stage clinical development aimed at treating WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and has potential applications in a broad range of cancer and autoimmune diseases. X4 Pharmaceuticals is dedicated to advancing its pipeline through scientific innovation and rigorous clinical studies, with the objective of improving the lives of patients battling serious diseases. Through its research and development efforts, the company aims to unlock the full potential of its therapies by addressing underserved medical needs.